Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 484

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 484
---
 Company Limited             | Vietnam              |                                         100.0 |
| Sanofi Vietnam Shareholding Company Limited        | Vietnam              |                                          85.0 |

* Main significant subsidiaries as of December 31, 2024 .

| SANOFIFORM 20-F2024 | F-103 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

F.2. Principal investments accounted for using the equity method

|                                            |               | Financial interest (%) as ofDecember 31, 2024 |
|:-------------------------------------------|:--------------|----------------------------------------------:|
| Haleon US, LP                              | United States |                                          11.7 |
| Infraserv GmbH & Co. Höchst KG             | Germany       |                                          31.2 |
| Maphar                                     | Morocco       |                                          48.3 |
| MCM Vaccine BV                             | Netherlands   |                                          50.0 |
| MSP Vaccine Company (formerly MCM company) | United States |                                          50.0 |
| EUROAPI                                    | France        |                                          29.6 |

G/ Event subsequent to December 31, 2024 During the meeting of the Board of Directors on January 29, 2025, the Board authorized Sanofi to repurchase the Company's shares, for an amount not exceeding € 5billion , under the terms and conditions set by the General Meeting of April 30, 2024 in its 19th resolution. As part of this authorization, Sanofi entered into a share buyback agreement with its historical shareholder L'Oréal on February 2, 2025 for the acquisition of 2.34% of its share capital, or the equivalent of 29,556,650 shares , for a total amount of approximately € 3billion , representing a price of € 101.50 per share. The conclusion of this agreement was approved by the Board of Directors on the same day prior to the signing of said agreement and in accordance with the procedure of Articles L. 225-38 et seq. of the French Commercial Code. In addition, on February 6, 2025, Sanofi entered into a mandate with an investment services provider to repurchase its own shares for a maximum amount of € 2billion , between February 7, 2025 and December 31, 2025 at the latest.

| F-104 | SANOFIFORM 20-F2024 |

| Notes                                                                                                                                                                                                                                                             |
| ................................................................................................................................................................................................................................